High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy
Status:
Withdrawn
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The primary endpoint of this study is to determine what percentage of patients receiving
high-dose Cyclophosphamide may experience a halt in the worsening of their disease or
experience improvement of their disease and for how long the benefit may last.